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Abstract 6 
The beneficial effects of vitamin D supplementation for a number of health-related issues, 7 
including the prevention of diabetes, are a topic of intense discussion. Data from 8 
epidemiological studies suggest a correlation between vitamin D deficiency and higher 9 
prevalence of both type 1- and type 2–diabetes. In animal models, vitamin D deficiency 10 
predisposes to diabetes, whereas vitamin D supplementation prevents disease. Still, well-11 
designed clinical intervention studies are lacking. Here, we discuss evidence available on a 12 
role for vitamin D in diabetes and propose that vitamin D deficiency should be avoided 13 
especially in all at-risk people. This should be possible by implementing global guidelines and 14 
by focusing on daily dietary supplementation with small doses of vitamin D.  15 
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Vitamin D and type 2 diabetes 16 
A physiological role for vitamin D in maintaining normal glucose metabolism is proposed, as 17 
the vitamin D receptor (VDR) is found in all insulin-responsive tissues as well as in the 18 
pancreatic beta-cells. Thus, deficiency in vitamin D (Box 1) is one of the environmental 19 
factors suspected of contributing to the growing epidemic of T2D (Box 2). As discussed 20 
below, data from epidemiological observations link vitamin D deficiency to glucose 21 
intolerance or T2D − either through a direct action via VDR or indirectly via the effects of 22 
vitamin D deficiency on calcium levels. Basic and translational research data also suggest that 23 
correcting vitamin D deficiency improves both beta-cell function and insulin sensitivity. 24 
Unfortunately, well-designed adequately-powered clinical trials that unequivocally support or 25 
refute a therapeutic role for vitamin D in T2D are still lacking. 26 
 27 
Association studies and epidemiology 28 
Genetic polymorphisms could help identify groups that are more susceptible to vitamin D 29 
deficiency and to developing T2D. Contrasting results have been published on the importance 30 
of allelic variations of vitamin D-related genes in the occurrence of insulin resistance and 31 
T2D. Despite reported correlations between VDR gene polymorphisms, especially the FokI 32 
single nucleotide polymorphism (SNP) [1], and insulin secretory responses to glucose [2, 3] 33 
and insulin resistance [4], case-control studies have failed to show differences in frequencies 34 
of VDR polymorphisms between T2D patients and healthy controls [5, 6]. Most associations 35 
so far have been found in Asian populations and additional studies in other populations are 36 
required. 37 
As elegantly reviewed by Mezza et al. [7], many association studies link vitamin D deficiency 38 
to an increased risk for the development of T2D. In addition, the European Prospective 39 
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Investigation into Cancer (EPIC)-Norfolk study [8] and a new meta-analysis of prospective 40 
studies demonstrated a significant association between low 25(OH)D concentrations and risk 41 
of T2D, irrespective of gender, study duration, sample size, diabetes diagnostic criteria, or 42 
type of 25(OH)D assay used [9]. Epidemiological studies show correlations between low 43 
serum 25(OH)D concentrations and increased insulin resistance, as well as impaired beta-cell 44 
function (reviewed in [10]). The large cross-sectional National Health and Nutrition 45 
Examination Survey (NHANES) study showed an inverse correlation between serum 46 
25(OH)D concentration and T2D incidence and insulin resistance [11]. The Medical Research 47 
Council Ely Study 1990-2000 also reported an inverse relationship between vitamin D status 48 
and glycemia [12]. A recent study in non-obese Asian patients, confirmed this inverse 49 
correlation between vitamin D status and T2D risk, insulin resistance and beta-cell function 50 
[13]. Clear correlations are also observed between vitamin D deficiency and gestational 51 
diabetes, considered a precursor of T2D, as confirmed in a recent systematic review [14].  52 
However, some reports failed to find an association between serum concentrations of 53 
25(OH)D and T2D risk, in particular when correcting for body mass index (BMI) and obesity 54 
[15]. The latter are major confounders, as excess body fat is the single most important 55 
contributor to the development of T2D and most T2D patients have an increased BMI. Serum 56 
25(OH)D concentration on the other hand is inversely correlated with body fat content and 57 
BMI thus introducing an important confounder when interpreting data linking vitamin D 58 
deficiency and T2D [16]. Explanations for the low concentrations of serum 25(OH)D in obese 59 
individuals can be: 1) inadequate dietary input and reduced cutaneous synthesis linked to 60 
unhealthy lifestyle, 2) negative feedback from high concentrations of 1,25(OH)2D and 61 
parathyroid hormone (PTH) on hepatic 25(OH)D synthesis, or 3) a larger vitamin D storage 62 
capacity (sequestration) in body tissue, particularly fat. However, volumetric dilution could  63 
account for the variability in serum 25(OH)D concentration attributable to obesity: once 64 
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concentrations of circulating 25(OH)D are adjusted for body size, the difference between 65 
obese and lean subjects disappears [17].  66 
Taken together, strong evidence from epidemiology suggests that vitamin D insufficiency 67 
predisposes to beta-cell dysfunction, insulin resistance and T2D. 68 
Translational research 69 
Impaired glucose tolerance due to beta-cell dysfunction was one of the first extra-skeletal 70 
effects of vitamin D deficiency described in experimental animal models [18], a defect 71 
restored by vitamin D supplementation [19] (Figure 1). A few intervention studies in rodent 72 
models of T2D support the hypothesis that vitamin D treatment improves glucose homeostasis 73 
and T2D [20]. Mechanistically, circulating 1,25(OH)2D can bind directly to VDR in beta-74 
cells and 1,25(OH)2D directly stimulates the expression of insulin receptor and promotes 75 
insulin-mediated glucose transport in vitro (reviewed in [21]). Furthermore, exposure of 76 
pancreatic islets to 1,25(OH)2D affects the expression of genes involved in cellular growth, 77 
cytoskeletal organization, intracellular trafficking, formation of intercellular junctions, and 78 
insulin secretion [22]. 1,25(OH)2D may also reduce the low grade chronic inflammation 79 
present in obesity and T2D, as 1,25(OH)2D decreases the production of inflammatory 80 
products like cytokines by activated macrophages and inflammation impairs both beta-cell 81 
function and insulin sensitivity [23]. Finally, vitamin D deficiency leads to increased activity 82 
of the renin angiotensin system (RAS) [24], known to impair beta-cell function and peripheral 83 
insulin sensitivity, and 1,25(OH)2D suppresses the RAS [25].  84 
Caution is needed however, when interpreting in vivo studies, as vitamin D deficiency also 85 
affects serum calcium levels and calcium is a crucial ion in insulin secretion and action [26]. 86 
Hypo- or hyper-calcemia impair the proper function of pancreatic islets and affect insulin 87 
sensitivity of target tissues. The alteration of calcium levels by vitamin D deficiency as well 88 
as administration of high doses of vitamin D or 1,25(OH)2D creates a major confounder in 89 
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data interpretation. Experimental data show that VDR knock-out (KO) mice have completely 90 
normal glucose tolerance and beta-cell function when calcium levels are kept normal using 91 
high lactose and high calcium diets [27].  92 
In conclusion, in vitro studies suggest a direct role for the vitamin D system in beta-cell 93 
function and insulin sensitivity, and data from animal models imply a direct relationship 94 
between vitamin D deficiency and T2D.  95 
 96 
Clinical trials 97 
To date, there is still a lack of large scale, blinded trials demonstrating the beneficial effect of 98 
vitamin D supplementation on the prevention of T2D (measured by improved beta-cell 99 
function or improved insulin sensitivity). Older, small scale trials [28] have suggested that 100 
high doses of vitamin D reverse T2D in vitamin D deficient populations such as dialysis 101 
patients, and more recent small scale trials show a positive effect of vitamin D supplements 102 
on insulin sensitivity, both in healthy and vitamin D-deficient individuals [29, 30]. Studies 103 
focusing on pre-diabetes or gestational diabetes in young individuals demonstrate improved 104 
insulin sensitivity by vitamin D supplementation [31]. In contrast, a recent double-blind, 105 
randomized, placebo-controlled trial demonstrated that high-dose vitamin D supplements 106 
(11,200 IU per day for 2 weeks, followed by 5,600 IU per day for 10 weeks) could not reduce 107 
insulin resistance, blood pressure, inflammation or glycosylated hemoglobin (HbA1c) in 108 
patients with established T2D [32]. Hope is now set on the more than 25 registered trials 109 
investigating the impact of vitamin D supplements on the prevention of insulin resistance, 110 
T2D or gestational diabetes (www.clinicaltrials.gov).  111 
 112 
Vitamin D and type 1 diabetes 113 
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Vitamin D (Box 1) might be a candidate influencing T1D incidence (Box 3), based on results 114 
from association studies, epidemiology, and from basic and translational studies. For instance, 115 
increased prevalence of T1D with increased latitude suggests a link with lower availability of 116 
sunshine and thus less potential synthesis of vitamin D in the skin (see below). In addition, 117 
VDR is present in beta-cells as well as many immune cells and high doses of 1,25(OH)2D are 118 
able to alter T1D presentation in animal models. However, clinical trials have so far failed to 119 
substantiate the therapeutic potential of vitamin D in T1D prevention and intervention (see 120 
below). It is important to note here that several randomized controlled trials using vitamin D 121 
have been unsatisfactory, possibly due to using too low doses or too large intermittent doses, a 122 
too short treatment period, looking at people who already have dysglycemia, etc. 123 
 124 
Association studies- Epidemiology 125 
In recent years, many epidemiological and genetic studies have attempted to link vitamin D 126 
deficiency or defects in the vitamin D system to the increased prevalence of autoimmune 127 
diseases.  128 
The hypothesis that vitamin D deficiency plays a role in T1D is supported by reports that the 129 
incidence of T1D follows a clustered seasonal pattern. For example, the US-based SEARCH 130 
study concluded that spring births were associated with increased likelihood of T1D, but 131 
possibly not in all US regions [33]. Similarly, significantly more children with diabetes were 132 
born during the Spring-Summer than in Autumn-Winter in Greece during the period 1978-133 
2008 [34]. Seasonal variation was also found in clinical onset of T1D. In Sardinia and 134 
Finland, two areas with the highest incidence of T1D worldwide, a significant seasonal 135 
pattern was found for two age-groups (0-9 and 10-14 years)[35]. In Germany, Greece and in 136 
Denmark, seasonal variation was also observed with cases increasing during the cold months 137 
[34, 36, 37]. A large, global and standardized study based on incidence data from the World 138 
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Health Organization Diabetes Mondiale (WHO DiaMond) Project (0-14 years old children, 139 
over the period 1990-1999) confirmed that seasonal variation in T1D incidence rates in 140 
children under 15 years of age is a real phenomenon [38]. 141 
Studies focusing on latitude and UVB irradiance have revealed an inverse correlation between 142 
the monthly hours of available sunshine and the incidence of T1D [39-41]. Where initial data 143 
showed an inverse association of T1D prevalence and latitudinal gradients in the Northern 144 
Hemisphere [42], later studies, for example in Australia and in Newfoundland and Labrador, 145 
suggested that actual exposure to UVB radiation may be geospatially associated with the 146 
incidence of T1D, rather than the degree of latitude itself [40, 41]. Analysis of data from the 147 
Diamond project indeed showed an association between low UVB irradiance and high 148 
incidence rates of T1D after controlling for per capita health expenditure [39]. Strikingly, 149 
incidence rates of T1D approached zero in regions worldwide with high UVB irradiance [39]. 150 
Because vitamin D is predominantly synthesized by UVB exposure of the skin, studies have 151 
assessed and revealed a worldwide association between vitamin D deficiency and the onset of 152 
T1D. North Indian [43], Italian [44], Swedish [45], and British [46] children or young adults 153 
with newly diagnosed T1D had lower concentrations of serum 25(OH)D than healthy 154 
controls. An increased prevalence of vitamin D deficiency in children and adolescents with 155 
T1D compared with non-diabetic individuals was also observed in Swiss [47], American [48], 156 
Australian [49], and Qatari [50] populations. Interestingly, vitamin D supplementation in 157 
early childhood has been shown to reduce the risk for T1D [51]. 158 
Also genetic studies have searched for a link between the vitamin D system and T1D. SNPs in 159 
three key genes of enzymes involved in vitamin D metabolism, namely CYP27B1, DHCR7, 160 
and CYP2R1, affect concentrations of serum 25(OH)D [52] and are associated with 161 
susceptibility to T1D [46, 53]. SNPs in CYP24A1 (encoding for the vitamin D-catabolizing 162 
enzyme) are associated with lower vitamin D status [52] but not with susceptibility to T1D 163 
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[46, 53]. A link between SNPs in the DBP gene and T1D has also been demonstrated [54]. 164 
The search for an association between VDR genetic polymorphisms and T1D has yielded 165 
conflicting. Several small studies have linked VDR gene variations to T1D and a recent meta-166 
analysis suggests that at least one of four known polymorphisms in the VDR gene is 167 
associated with a higher risk for T1D in Asians [55]. However, in contrast, an earlier meta-168 
analysis [56] and the largest association studies [57, 58] found no association between VDR 169 
polymorphisms and T1D.  170 
Thus, it can be concluded that epidemiology points towards a role for the vitamin D system in 171 
the onset of T1D, but data are conflicting. 172 
Translational research 173 
The awareness of a role for vitamin D in the regulation of immune responses was triggered by 174 
the discovery that VDR is expressed in almost all immune cells of the innate and adaptive 175 
immune system. 1,25(OH)2D or its analogs can effectively inhibit dendritic cell 176 
differentiation and immune activation by inhibiting the surface expression of MHC class II-177 
complexed antigen, co-stimulatory molecules and the production of the proinflammatory 178 
cytokines interleukin-12 and -23 (IL-12, IL-23) [59] (Figure 2). This causes an indirect shift 179 
in T cell polarization from a T helper (Th)1/Th17 to a Th2 phenotype and favors regulatory T 180 
cell (Treg) development [60]. In addition, 1,25(OH)2D can also act directly on T cells [61, 181 
62], reducing Th1/Th9/Th17 responses [63], increasing Th2 responses and promoting a Treg 182 
profile in T cells from healthy individuals [62]. 183 
In NOD mice, a rodent model for T1D, chronic administration of 1,25(OH)2D inhibits 184 
insulitis and delays diabetes onset [64]. These effects might stem from the effects of 185 
1,25(OH)2D on immune cells, as NOD mice treated with 1,25(OH)2D display a Th1 to Th2 186 
shift in the pancreas and pancreas-draining lymph nodes [65], have decreased Th1 cell 187 
infiltration in the pancreas and increased CD4+CD25+ Tregs in the pancreatic lymph nodes 188 
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[66]. A major issue with the doses needed to achieve this protection are the hypercalcemia 189 
and bone-effects (decalcification in the presence of calcium-poor diet) observed. Structural 190 
analogues of vitamin D that share the immune effects, but have greatly reduced effects on 191 
calcium and bone compared to 1,25(OH)2D, can avoid these side-effects [62]. 192 
Direct effects of 1,25(OH)2D on the beta-cells are also documented (see above, section on 193 
T2D), but data on protection against cytokine-impaired insulin release [22] and cytokine-194 
mediated beta-cell death [67] have been inconsistent, likely because of different experimental 195 
conditions and models used. Moreover, 1,25(OH)2D may improve beta-cell function because 196 
it can limit chemokine expression [67], partly normalize the gene expression of MHC class I 197 
molecules, and decrease the density of MHC class I proteins of beta-cells. This can effectively 198 
reduce T cell infiltration and activation in the islets [67], consequently decreasing the pro-199 
inflammatory cytokines in the micro-environment. 200 
 201 
Clinical trials 202 
Several retrospective studies have suggested that supplementation with regular vitamin D in 203 
early life lowers the risk of T1D onset. For instance, a birth-cohort study in Finland in 1966 204 
showed an almost 80% reduction in the risk for T1D development by the intake of the daily 205 
recommended (at that time) dose of 2,000 IU of vitamin D during the first year of life [51]. 206 
This was confirmed in 1999 by the EURODIAB study, which reported a 33% reduction in 207 
T1D in children receiving (unspecified doses of) vitamin D supplements in early childhood 208 
[68]. Meta-analysis of data from four case-control studies and one cohort-study showed that 209 
the T1D prevalence was 29% lower in infants receiving vitamin D supplements [69]. Overall, 210 
these studies suggest that vitamin D-mediated diabetes protection may be dose-dependent. 211 
However, some studies did not find a correlation between T1D prevention and vitamin D 212 
supplementation. In Norway, intake of cod-liver oil by children under 1 y resulted in a (not 213 
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statistically significant) tendency of lowered T1D incidence [70] and the ABIS study in 214 
Sweden found that the use of vitamin D-containing supplements during pregnancy was 215 
associated with reduced development of autoantibodies to GAD or IA-2A in the offspring at 1 216 
year, but not at 2.5 years [71]. Despite the fact that some studies failed to show an association 217 
between reduced T1D risk and vitamin D supplementation during infancy, none of them were 218 
associated with an increased risk. 219 
Doses of 2,000 IU/d regular vitamin D were regarded as high 10 years ago, and they still are, 220 
based on toxicity and side-effect thresholds. However, it is suggested that the currently 221 
recommended daily allowance (RDA) of 600 IU/d (age up to 70 years) might be inadequate to 222 
achieve the intended effects on immune cells or beta-cells. For instance, in an experimental 223 
system, Cheng et al. found that ten times the concentrations of 1,25(OH)2D normally seen in 224 
the circulation were needed for optimal effects on insulin secretory responses to glucose [24]. 225 
For that reason, several recent studies evaluate the effects of much higher doses of regular 226 
vitamin D or 1,25(OH)2D (see below). 227 
So, what about intervention studies in recent-onset T1D patients? Large scale studies are 228 
again lacking. Some small studies gave a hint that safe doses of vitamin D may possibly 229 
dampen beta-cell loss allowing better glucose control after T1D onset, but small sample sizes, 230 
short duration of follow-up and lack of control groups constitute major limitations of the 231 
reported studies. Confirmation at a much larger scale is therefore needed. For instance, the 232 
IMDIAB XI and XIII studies showed that administration of 0.25 µg 1,25(OH)2D daily or on 233 
alternate days was safe but nevertheless failed to reduce loss of beta-cell function [72], even 234 
in patients with high C-peptide at diagnosis [73]. Again, the use of too low doses or too short 235 
regimens of regular vitamin D or 1,25(OH)2D administration might be responsible for this 236 
failure. In addition, in many studies, it is unclear whether the administered vitamin D 237 
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supplements restored existing deficiencies or augmented circulating vitamin D in already 238 
sufficient individuals. 239 
Several trials in T1D patients are registered at www.clinicaltrials.gov. A study at the 240 
universities of Graz and Vienna in Austria will provide data on how ultra-high monthly bolus 241 
vitamin D supplementation affects Tregs and metabolic outcome in T1D patients 242 
(NCT01390480). This study should confirm the increased Treg levels observed in vitamin D-243 
supplemented healthy individuals [74] and form a direct immunological basis for using 244 
vitamin D supplementation in T1D. An alternative approach is to use vitamin D in 245 
combination treatment. A completed unpublished study (NCT00873925) combined vitamin D 246 
with omega-3 and umbilical cord blood (UCB, used because it contains highly functional 247 
populations of Tregs), despite earlier failure of transfusion of autologous UCB to preserve C-248 
peptide in young children with T1D [75]. The DIABGAD study will test the efficacy of alum-249 
formulated GAD65 (GAD-Alum, Diamyd), in combination with vitamin D and ibuprofen 250 
(NCT01785108), notwithstanding earlier failure of GAD-Alum treatment to significantly 251 
reduce the loss of stimulated C-peptide or improve clinical outcomes in T1D patients [76]. As 252 
a reminder, GAD-alum vaccination aims at intervening in the autoimmune destructive process 253 
by modulating the immune system in a discrete, antigen-specific (GAD is a major auto-254 
antigen in T1D) manner to prevent the destruction of beta-cells. 255 
One of the major obstacles for translating the successful animal data to humans is the need for 256 
supra-physiological doses to modulate immune responses, as these elicit hypercalcemia, 257 
hypercalciuria and kidney stones. The use of structural analogs of 1,25(OH)2D with reduced 258 
calcemic effects but similar immunoregulatory activity might overcome this issue, but no 259 
trials are registered to investigate effects of vitamin D analogues on T1D prevention or 260 
reversal. 261 
 262 
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Concluding remarks and future perspectives 263 
Vitamin D deficiency is a threat to health in general, with a suggestive link to the two most 264 
common forms of diabetes, T1D and T2D. Receptors for vitamin D are found in all tissues 265 
and organs involved in the diseases - from the common player that is the beta-cell, to the 266 
immune system and the insulin target organs, muscle, adipose tissue and liver. Several 267 
enzymes responsible for 25-hydroxylation of vitamin D and even the CYP27B1-hydroxylase, 268 
responsible for the final activation of 25(OH)D to 1,25(OH)2D, are also widely expressed in 269 
human tissues involved in the pathogenesis of both T1D and T2D, suggesting the possibility 270 
of local production and function of 1,25(OH)2D . Association studies and epidemiology data 271 
convincingly point to a link between vitamin D deficiency, glucose intolerance and T2D, and 272 
also suggest that vitamin D deficiency is associated with a higher risk for T1D in genetically 273 
susceptible individuals. Basic science and animal models of the diseases point towards the 274 
potential of the vitamin D system not only being one of the contributors to the changing 275 
behavior of the diseases worldwide, but also being of therapeutic use, with supplements of 276 
vitamin D or of its most active form, 1,25(OH)2D, altering the course of the disease. 277 
However, clinical trial data demonstrating a therapeutic role for vitamin D or its metabolites 278 
and analogues are lacking. These trials are not easy to conduct, because vitamin D is present 279 
in many ‘fortified’ foods and the hype over vitamin D has resulted in increased consumption 280 
in recent years (via over-the-counter supplements). Trials are nevertheless desperately needed 281 
to confirm or refute a therapeutic potential of this compound (see Outstanding questions box). 282 
One should not forget that vitamin D is a fat-soluble vitamin and that toxicity is observed 283 
when chronically supra-physiological doses are administered. Until satisfactory randomized 284 
controlled trial data is available, the only sound advice that can be given to people at risk for 285 
T1D and T2D, is to avoid vitamin D deficiency. This can easily be achieved by following the 286 
recent guidelines from the Institutes of Medicine (IOM, www.iom.edu). If all individuals 287 
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achieved recent IOM guideline intakes of vitamin D [77], and deficiency were to be virtually 288 
eliminated, then, if vitamin D does have a role in protection against T1D and T2D, this alone 289 
might lead to reductions in the future incidence and prevalence of T1D and T2D, respectively.  290 
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Box 1: Vitamin D metabolism 490 
In humans, vitamin D is mainly derived from endogenous vitamin D production as a result of 491 
skin exposure to ultraviolet B (UVB) light and only a minor portion is obtained via food 492 
intake of fortified milk and dairy products, eggs and wild oily sea fish [21]. Vitamin D is a 493 
fat-soluble precursor of the major circulating 25-hydroxyvitamin D (25(OH)D) metabolite 494 
which is transformed – predominantly in the kidney – by a single enzyme 1α-hydroxylase 495 
(1α(OH)ase; CYP27B1) into the most active hormonal metabolite 1,25-dihydroxyvitamin D 496 
(1,25(OH)2D), known to stimulate bone mineralization through its capacity to stimulate 497 
intestinal calcium absorption. Many immune cells also contain the machinery for the two-step 498 
conversion of vitamin D to 1,25(OH)2D [23]. Moreover, 1,25(OH)2D can be produced locally 499 
in the pancreas from the main circulating form, 25(OH)D, because 1α-hydroxylase is present 500 
in islets [78]. 25(OH)D itself also has some biological activity, but 1,25(OH)2D has about  501 
1000 times the affinity for the vitamin D receptor (VDR) than 25(OH)D. All vitamin D 502 
metabolites are transported by the vitamin D-binding protein (DBP) that has a different 503 
affinity for the individual metabolites [79].Geographic distribution and seasonality, skin 504 
pigmentation, age, and lifestyle may predispose certain people to a higher risk of developing 505 
vitamin D insufficiency (defined as 25(OH)D concentrations 20 to 30 ng/mL or 50 to 75 506 
nmol/L), or deficiency (25(OH)D concentration <20 ng/mL or <50 nmol/L). 507 
 508 
Box 2. Type 2 diabetes. 509 
The last decades have confronted us with a steep rise in the prevalence of type-2diabetes 510 
(T2D), with estimates for 2030 of more than 550 million people with diabetes worldwide 511 
(www.idf.org). The epidemic is noticeable in all continents, with the highest prevalence at 512 
present in the US. The most dramatic growth is forecasted to happen in new economies, with 513 
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a near-doubling of prevalence predicted in Asia, Africa and Latin-America in the next decade. 514 
Contributors to the rise in T2D include a number of environmental factors such as increased 515 
sedentarism that drives the increasing occurrence of overweight and obesity, but also 516 
increasing age predisposes to T2D [80]. A major hallmark of T2D is insulin resistance, 517 
namely the inability of cells to respond to the normal actions of insulin to control glucose 518 
homeostasis. Insulin resistance is observed in organs such as liver, fat tissue and muscle, but 519 
also contributes to a progressive failure of the pancreatic islet beta-cells to produce insulin. 520 
Clinically, T2D is treated with drugs that reduce insulin resistance (e.g. metformin) and/or 521 
increase insulin secretion by the beta-cell (e.g. sulphonylurea). Recently, therapies 522 
suppressing glucagon secretion in pancreatic islet alpha-cells, modulating appetite, or 523 
decreasing gastric emptying (e.g. incretin-based therapies) or affecting glucose-reabsorption 524 
in the kidney (e.g. SGLT2 blockade) have been added to the arsenal of  glucose lowering 525 
therapies (reviewed in [81]). 526 
 527 
Box 3. Type 1 diabetes (T1D). 528 
Type 1 diabetes (T1D) is one of the most common chronic diseases of childhood and is an 529 
autoimmune disorder that results in the destruction of the insulin-producing beta-cell in the 530 
pancreas, rendering the patient dependent on insulin administration for survival (reviewed in 531 
[82, 83]. The prevalence of T1D ranges from less than 5 in every 100,000 individuals in 532 
eastern countries to as many as 40 in every 100,000 individuals in European and other 533 
western countries [84]. In contrast to T2D, T1D is not increasing dramatically in prevalence, 534 
but shifts towards onset at younger ages [84]. The peak incidence of disease onset is between 535 
6 and 15 years of age, and a second peak occurs later in adolescence. Thus, when studying 536 
only children and adolescents, the numbers increase dramatically. Environmental factors, such 537 
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as viral infections, changes in gut microbiota and dietary components, are considered culprits 538 
for this alteration in clinical presentation [82, 85]. 539 
Preclinical and clinical studies have provided insight into the cells, antigens, and mechanisms 540 
involved. For instance, B cells have been documented as antigen-presenting cells and 541 
producers of auto-antibodies, T cells as producers of proinflammatory mediators and 542 
executioners of beta-cells killing, and regulatory T cells (Tregs) as cells counteracting the 543 
autoimmune attacks by effector cells [82, 83]. Important for clinical diagnosis, more than 544 
90% of individuals with T1D test positive for at least one auto-antibody. Moreover, the 545 
presence of auto-antibodies identifies relatives of patients who are at a high risk for the 546 
disease. Typical targets of these auto-antibodies include antigens such as glutamic acid 547 
decarboxylase (GAD65), I-A2, insulin, islet-specific glucose-6-phosphatase catalytic subunit-548 
related protein (IGRP), zinc transporter 8 (ZNT8) and islet cell auto-antigen (ICA)[86]. 549 
 550 
Outstanding Questions box: 551 
• Will eradication of vitamin D deficiency affect type 1 or type 2 diabetes presentation? 552 
• Can supplements of vitamin D, over and above the doses advised for bone health, 553 
prevent type 1 or type 2 diabetes? 554 
• Can structural analogues of vitamin D or 1,25(OH)2D that affect the immune system 555 
without causing hypercalcemia, prevent or reverse type 1 or type 2 diabetes in 556 
humans? 557 
• Can ex vivo treatment of immune cells offer a way to safely exploit the immune 558 
modulatory properties of vitamin D? 559 
 560 
  561 
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Figure Legends 562 
Figure 1. Effect of vitamin D on pathophysiology in type 2 diabetes. Type 2 diabetes is 'a 563 
dual disease' characterized by increased insulin resistance followed by beta-cell dysfunction. 564 
As a consequence, insulin can no longer block lipolysis in fat tissue, glucose production in the 565 
liver and stimulate glucose uptake in the muscle. Biologically active vitamin D, 1,25(OH)2D 566 
(depicted as Vit D), can reduce beta-cell dysfunction by restoring impaired insulin production 567 
and islet viability and by dampening T2D-associated inflammation in the pancreas. Vitamin D 568 
can also counteract increased insulin resistance. MHC I: Major Histocompatibility Complex 569 
1; MHC II: Major Histocompatibility Complex 2; NO: nitric oxide. 570 
Figure 2. Effect of vitamin D on immune and beta-cell-related events in type 1 diabetes 571 
pathogenesis. Beta-cells and various immune cells express VDR, the receptor for 572 
1,25(OH)2D (depicted as Vit D). 1,25(OH)2D  inhibits the expression of MHC class II and 573 
co-stimulatory molecules (such as CD40, CD80, CD86) on the cell surface of antigen-574 
presenting cells (APC), including DCs, and inhibits the release of pro-inflammatory 575 
cytokines, such as IL-12 and IL-23. In this way, 1,25(OH)2D indirectly shifts CD4+ T cell 576 
polarization from a pro-inflammatory Th1/Th17 to an anti-inflammatory Th2/Treg phenotype. 577 
1,25(OH)2D also directly modulates T cell responses, by inhibiting inflammatory Th1- and 578 
Th17 cytokines and upregulation of Th2 cytokines. In addition, 1,25(OH)2D reduces 579 
pancreatic infiltration by Th1 and Th17 cells. 1,25(OH)2D also limits surface expression of 580 
MHC class I and II on beta-cells, as well as chemokine release by beta-cells, leading to 581 
reduced pancreatic recruitment and/or retention of T cells. β: beta-cell; Vit D: 1,25(OH)2D; 582 
MHC I: Major Histocompatibility Complex 1; MHC II: Major Histocompatibility Complex 2; 583 
IFNγ: Interferon-gamma; IL: Interleukin; Treg: Regulatory T cell; DC: dendritic cell; CD: 584 
Cluster of Differentiation.  585 
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